KURA — Kura Oncology, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on KURA
| date | signal | measured base rate |
|---|---|---|
| 2026-08-18 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-08-18 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-08-17 | Conviction buy by an officer insider | -1.03% over 21 days · t = -2.24 · n = 1,083 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-09 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-07-08 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-19 | Bair Teresa Brophy Chief Legal Officer | Open-market sale 10b5-1 plan | 31.5K | 12.63 | 397.7K |
| 2026-08-17 | WILSON TROY EDWARD President and CEO | Open-market purchase | 100.0K | 11.12 | 1.1M |
| 2026-06-18 | Leoni Mollie Chief Medical Officer | Open-market sale 10b5-1 plan | 84.9K | 9.82 | 834.3K |
| 2026-05-21 | Powl Brian T. Chief Commercial Officer | Open-market sale 10b5-1 plan | 10.0K | 11.00 | 110.0K |
| 2026-05-19 | FORD KATHLEEN Chief Operating Officer | Open-market sale 10b5-1 plan | 2.3K | 9.08 | 20.5K |
| 2026-05-19 | Powl Brian T. Chief Commercial Officer | Open-market sale 10b5-1 plan | 339 | 9.21 | 3.1K |
| 2026-05-18 | Bair Teresa Brophy Chief Legal Officer | Open-market sale 10b5-1 plan | 2.3K | 9.38 | 21.2K |
| 2026-03-23 | WILSON TROY EDWARD President and CEO | Option exercise | 6.1K | 6.15 | 37.5K |
| 2026-03-18 | Malley Thomas Director | Option exercise | 10.0K | 3.12 | 31.2K |
| 2026-01-27 | Powl Brian T. Chief Commercial Officer | Open-market sale | 4.8K | 8.46 | 41.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 78.4M | 9.6M |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 69.7M | 8.6M |
| BVF INC/IL | 68.7M | 8.4M |
| STATE STREET CORP | 36.7M | 4.5M |
| VANGUARD CAPITAL MANAGEMENT LLC | 30.8M | 3.8M |
| ARMISTICE CAPITAL, LLC | 30.4M | 3.7M |
| Prosight Management, LP | 27.3M | 3.4M |
| Deep Track Capital, LP | 21.5M | 2.6M |
| AQR CAPITAL MANAGEMENT LLC | 17.3M | 2.1M |
| GEODE CAPITAL MANAGEMENT, LLC | 16.5M | 2.0M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 144 | 2026-08-21 | — | on EDGAR ↗ |
| 4 | 2026-08-21 | 2026-08-19 | on EDGAR ↗ |
| 144 | 2026-08-19 | — | on EDGAR ↗ |
| 4 | 2026-08-17 | 2026-08-17 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-12 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-12 | 2026-08-12 | on EDGAR ↗ |
| 8-K | 2026-07-29 | 2026-07-24 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Kura Oncology, Inc. (KURA) filed form 4 · 2026-08-21 · SEC EDGAR
- Kura Oncology, Inc. (KURA) filed form 144 · 2026-08-21 · SEC EDGAR
- Kura Oncology (KURA) Q2 2026 Earnings Call Transcript · 2026-08-19
- Kura Oncology, Inc. (KURA) filed form 144 · 2026-08-19 · SEC EDGAR
- Duos Technologies Posts Upbeat Q2 Results, Joins Amylyx Pharmaceuticals, Weave Communications And Other Big Stocks Moving Higher On Tuesday · 2026-08-18 · benzinga
- Kura Oncology stock rises on CEO insider purchase · 2026-08-17
Ask the AI about KURA
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →